Astec Lifesciences | Business Upturn

Astec LifeSciences approves audited financial results for FY26

Kinjal — Mon, 27 Apr 2026 15:13:34 +0000

Astec LifeSciences has announced the approval of its audited financial results for the quarter and financial year ended 31st March 2026. The decision was made during a Board meeting held on 27th April 2026.

The Board of Directors, following the recommendation of the Audit Committee, approved the standalone and consolidated financial results in accordance with Indian Accounting Standards (IND AS). The results include the Cash Flow Statement and the Statement of Assets and Liabilities as of 31st March 2026.

Additionally, the Board noted the Statutory Auditors’ Reports on the financial results, which were presented with an unmodified opinion. This indicates that the auditors found the financial statements to be in compliance with the applicable accounting standards and free from material misstatements.

The Board also addressed matters related to the upcoming 32nd Annual General Meeting (AGM), which is scheduled for 31st July 2026. The book closure dates for the AGM are set from 26th July to 30th July 2026.

Furthermore, the Board approved a proposal to seek shareholder approval via postal ballot for several items, including the appointment of Mr. Vishal Sharma and Mr. Burjis N. Godrej as Non-Executive Directors, the appointment and remuneration of Mr. Arijit Mukherjee as an Executive Director, the appointment of Mr. Mathew Eipe as an Independent Director, and approval for entering into material related party transactions for the financial year 2026-27.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Astec LifeSciences reports ₹161.3 crore income in Q4 FY26, a 34% increase

Arunika Jain — Mon, 27 Apr 2026 14:49:09 +0000

Astec LifeSciences Limited has announced its consolidated financial results for the fourth quarter and year ended 31st March 2026, showcasing significant growth in revenue and a reduction in losses.

In the fourth quarter of FY26, Astec LifeSciences reported a consolidated total income of ₹161.3 crore, marking a 34% increase compared to ₹120.3 crore in the same quarter of the previous fiscal year. The company’s consolidated EBITDA for Q4 FY26 stood at ₹11.8 crore, up from ₹6.3 crore in Q4 FY25, reflecting an 86.9% growth. Despite these improvements, the company reported a loss after tax of ₹7.7 crore in Q4 FY26, compared to a loss of ₹16.1 crore in Q4 FY25.

For the full fiscal year FY26, Astec LifeSciences achieved a consolidated total income of ₹453.2 crore, a 17.1% rise from ₹386.9 crore in FY25. The company reached an EBITDA breakeven with ₹0.5 crore in FY26, a significant turnaround from an EBITDA loss of ₹60.6 crore in FY25. However, the company reported a net loss of ₹80.9 crore in FY26, which is an improvement from the ₹134.7 crore loss in FY25.

The financial results were influenced by exceptional items related to regulatory changes in labour codes, which resulted in a financial impact of ₹2.1 crore, including gratuity and long-term compensated absences.

Chairperson Vishal Sharma commented on the performance, highlighting the strong revenue growth driven by improved volumes in both the Enterprise and Contract Manufacturing segments. This growth led to a significant margin expansion, with EBITDA growing to ₹11.8 crore in Q4 FY26 from ₹6.3 crore in Q4 FY25.

Astec LifeSciences continues to demonstrate a healthy sales mix of both exports and domestic sales, with exports reaching ₹103.7 crore in Q4 FY26, an 8% increase year-on-year, while domestic sales surged by 133.8% to ₹54.9 crore.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Astec LifeSciences reports 34% revenue growth in Q4 FY26 with ₹161.3 crore income

Business Desk — Mon, 27 Apr 2026 14:48:47 +0000

Astec LifeSciences Limited has announced its financial results for the fourth quarter and the financial year ending 31st March 2026, showcasing a robust performance. The company reported a consolidated total income of ₹161.3 crore for Q4 FY26, marking a 34% increase from ₹120.3 crore in the same quarter of the previous year.

The company’s consolidated EBITDA for the quarter stood at ₹11.8 crore, significantly up from ₹6.3 crore in Q4 FY25, indicating an 87% growth. Despite this, Astec recorded a loss after tax of ₹7.7 crore in Q4 FY26, compared to a loss of ₹16.1 crore in the corresponding quarter last year.

For the full financial year FY26, Astec reported a consolidated total income of ₹453.2 crore, up from ₹386.9 crore in FY25, reflecting a 17.1% growth. The company achieved an EBITDA breakeven of ₹0.5 crore for FY26, a significant improvement from an EBITDA loss of ₹60.6 crore in FY25. However, the company reported a loss after exceptional items and tax of ₹80.9 crore for FY26, compared to a loss of ₹134.7 crore in the previous year.

The exceptional items included a financial impact due to the revised wage definition under the new Labour Codes notified by the Government of India, which accounted for gratuity and long-term compensated absences amounting to ₹1.7 crore and ₹0.4 crore, respectively.

Chairperson Mr. Vishal Sharma highlighted the strong revenue growth driven by improved volumes in both the Enterprise and Contract Manufacturing segments. The company saw a sequential revenue increase of 29% over Q3 FY26, primarily due to Enterprise Volumes. This growth led to a significant margin expansion, contributing to the increased EBITDA.

Astec’s revenue from operations in Q4 FY26 showed a 37.1% increase in the Enterprise category and a 29.5% rise in Contract Manufacturing and New Products. Geographically, export revenues grew by 8% to ₹103.7 crore, while domestic revenues surged by 133.8% to ₹54.9 crore.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Astec LifeSciences appoints Vishal Sharma as chairperson following Nadir Godrej’s retirement

Arunika Jain — Mon, 13 Apr 2026 11:50:29 +0000

Astec LifeSciences has announced significant changes in its board of directors, including the retirement of Mr. Nadir Godrej as Chairperson and Director, effective 13th April, 2026. Mr. Godrej’s departure marks the end of an era, as he steps down after providing invaluable guidance and leadership to the company.

The board has expressed its deepest appreciation for Mr. Godrej’s contributions during his tenure. In his place, Mr. Vishal Sharma has been appointed as the new Chairperson and Additional Director (Non-Executive, Non-Independent), subject to shareholder approval. Mr. Sharma’s appointment is effective from the close of business hours on the same date.

Mr. Vishal Sharma brings a wealth of experience to the role, having served as Executive Director and Chief Executive Officer (Chemicals) at Godrej Industries Limited, the ultimate holding company of Astec LifeSciences. With 30 years of experience in the specialty and process chemicals sector, Mr. Sharma is well-versed in both operational and strategic roles across five continents.

In addition to Mr. Sharma’s appointment, the company has also noted the resignation of Mr. Burjis N. Godrej as Managing Director. Mr. Burjis Godrej has expressed a desire to focus more on Godrej Agrovet Limited, the parent company. However, he will continue to serve on the board as an Additional Non-Executive Director, pending shareholder approval.

These changes reflect Astec LifeSciences’ commitment to maintaining strong leadership and continuity at the board level, ensuring the company’s strategic objectives are met while fostering growth and innovation.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Astec LifeSciences confirms Rs 4.36 crore interest payment on debentures

Arunika Jain — Fri, 27 Mar 2026 13:29:40 +0000

Astec LifeSciences has confirmed the timely payment of interest on its non-convertible debentures, amounting to ₹4,36,10,000. The payment was made on the due date of 27th March 2026, as per the company’s regulatory filing.

The debentures, identified by ISIN INE563J08023, have an issue size of ₹49 crore. The interest payment frequency is set on a yearly basis, with no changes in the payment schedule. The record date for the interest payment was 11th March 2026, and the next due date for interest payment is 25th March 2027.

Astec LifeSciences has reported no delays or non-payments, ensuring compliance with the Securities and Exchange Board of India’s (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Astec Lifesciences shares rally sharply over 18% today: Details here

Aman Shukla — Wed, 25 Mar 2026 09:04:56 +0000

Astec Lifesciences shares witnessed a sharp rally on Wednesday, surging over 18% intraday and drawing strong investor attention on Dalal Street. The stock touched a high of ₹620.95 during the session, compared to its previous close of ₹524.00. As of 2:35 PM, the shares were trading 18.50% higher at Rs 620.95.

The stock opened at ₹529.60 and quickly gained momentum, hitting an intraday low of ₹527.95 before accelerating upward. As of 2:34 PM IST, trading volumes stood at a robust 30,33,929 shares, indicating heightened market participation.

The rally pushed the stock closer to its 52-week range, though it remains significantly below its 52-week high of ₹990.82. Its 52-week low stands at ₹513.40.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Astec Lifesciences shares rally over 7% today; Details here

Aman Shukla — Wed, 03 Dec 2025 06:58:37 +0000

Astec Lifesciences witnessed a sharp upward move in today’s session, with the stock rising more than 7% amid strong trading interest. The counter opened at ₹796.25, matching its previous close, and gained momentum through the session.

The stock touched an intraday high of ₹867.80, while the day’s low remained at ₹796.25. By 12:27 PM (IST), the traded volume had crossed 35.47 lakh shares.

Astec Lifesciences continues to trade within a wide 52-week range. Its 52-week low stands at ₹607.05, while the 52-week high is significantly higher at ₹1,254.26, reflecting the volatility the stock has seen over the past year.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Astec Lifesciences shares jump over 7% today; Details here

Aman Shukla — Fri, 21 Nov 2025 04:15:49 +0000

Astec Lifesciences saw a strong upswing in early Friday trade, with the stock rallying more than 7%. The share opened at ₹745, slightly above the previous close of ₹734.05, and quickly gained momentum to hit an intraday high of ₹790.00 as of 9:41. At the time of writing, Astec Lifesciences shares were trading 7.57% higher at Rs 789.60.

The surge in volumes added further strength to the move, with over 36 lakh shares changing hands during the early session. The day’s low stood at ₹744.95, indicating steady interest from investors through the morning.

Despite trading far below its 52-week high of ₹1,254.26, the stock continues to hold comfortably above its 52-week low of ₹607.05.